Cornea Department, Eye Research Center, Farabi Eye Center, Tehran Medical University, Qazvin Square, Tehran, Iran.
Cornea. 2011 Feb;30(2):215-8. doi: 10.1097/ICO.0b013e3181e291a6.
To report the effect of intrastromal injection of bevacizumab in an eye with extensive corneal stromal vascularization after deep anterior lamellar keratoplasty.
Bevacizumab (2.5 mg/1 mL) was injected into the deep corneal stroma of an eye with severe and extensive stromal vascularization.
Corneal vascularization regressed dramatically after deep stromal injection of bevacizumab with no recurrence after 6 months. Visual acuity was improved, and the patient's complaints subsided.
Corneal intrastromal injection of bevacizumab can be considered for management of intrastromal vascularization after deep anterior lamellar keratoplasty.
报告在深板层角膜移植术后广泛角膜基质血管化的眼中，行基质内注射贝伐单抗的效果。
对严重且广泛的基质血管化眼中的深层角膜基质注射贝伐单抗（2.5mg/1mL）。
贝伐单抗深层基质注射后，角膜血管化迅速消退，6 个月后无复发。视力提高，患者的主诉减轻。
对于深板层角膜移植术后的基质内血管化，可考虑行角膜内注射贝伐单抗治疗。
Zotero 插件